GET DAILY SIGNALSCytomX Therapeutics (CTMX) Q3 2026 Earnings: Revenue Decline Offset by Strong Cash Position
Key Takeaways
- Total revenue was approximately $1.7 million in the third quarter of 2026, down from $6.0 million in the same period a year earlier and well below consensus estimates.
- The company reported a net loss of $0.09 per share, slightly wider than some analyst expectations of a $0.07 per share loss.
- CytomX ended the quarter with $348 million in cash, cash equivalents, and investments, including $37 million received from Regeneron for selecting two additional targets under its expanded collaboration.
- Operating expenses rose to $25.2 million from $21.7 million a year ago, driven by higher research and development (R&D) and general and administrative costs.
- Investor focus remains on the lead candidate varsetatug masetecan (Varseta-M) and CX-801 as the company advances toward a planned registrational study.
- For more context, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Interested in automated trading ideas? Explore Trending AI Robots to see data-driven signals across the market.
Earnings Context and Why It Matters
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company that develops conditionally activated, masked PROBODY therapeutics designed to localize treatment to the tumor microenvironment. For a company of this stage, quarterly revenue is less meaningful than cash runway, clinical execution, and partnership milestones. The third quarter 2026 report matters because it shows how the business is absorbing the conclusion of prior collaboration revenue while funding an ambitious clinical program. In my view, investors are watching closely whether the balance sheet remains strong enough to advance Varseta-M toward a pivotal study, making the combination of declining top-line revenue and a growing cash position the central tension in this report.
Reported Results
For the third quarter ended September 30, 2026, CytomX reported total revenue of approximately $1.7 million, down from $6.0 million in the prior-year period. The decline was primarily attributed to the conclusion of the Astellas collaboration in the second quarter of 2026. Reported revenue came in well below the consensus estimate, which stood at roughly $10.4 million, and the company posted a net loss of $0.09 per share.
Total operating expenses were $25.2 million, up from $21.7 million a year earlier. Research and development expenses rose to $16.5 million from $15.3 million, driven by higher personnel-related costs and partially offset by lower Varseta-M spending due to the timing of manufacturing activities. General and administrative expenses increased to $8.7 million from $6.4 million, reflecting personnel-related expenses, consulting costs, and rent associated with the transition to a new headquarters.
On the balance sheet, the company ended the quarter with $348 million in cash, cash equivalents, and investments, up from $330 million at the end of the prior quarter. That figure included $37 million received from Regeneron after it selected two additional targets under the companies' recently expanded collaboration, underscoring the value of the company's partnership strategy even as recognized revenue declined. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market's response to the report reflected a familiar dynamic for clinical-stage biotechs: collaboration revenue is fading, but the clinical story and cash position remain the primary drivers of sentiment. The revenue miss versus consensus, combined with a slightly wider-than-expected net loss, weighed on the stock in the immediate aftermath of the release. At the same time, the strengthened balance sheet and the incremental Regeneron milestone provided a counterbalance, reminding investors that non-dilutive funding continues to flow in through partnerships. Sentiment remains cautious, with attention split between near-term financial results and the longer-term potential of the company's masked oncology pipeline. From what I see, this is important because it highlights how partnership milestones can support valuation even when top-line numbers soften.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central catalyst for CytomX is the advancement of Varseta-M, its masked antibody-drug conjugate (ADC, a targeted therapy that links an antibody to a cancer-killing drug) directed at EpCAM for metastatic colorectal cancer. Management has signaled plans to prioritize a single dose and move toward a registrational, or pivotal, study targeted for the first half of 2027. Data readouts and regulatory interactions around this program will be the most important near-term drivers.
Investors should also monitor the progress of CX-801, a masked cytokine being developed for metastatic melanoma, where initial data updates remain a key milestone. The Regeneron collaboration represents another lever, as future target selections or milestone payments could further bolster the cash position without dilution.
On the financial side, the trajectory of collaboration revenue will likely remain lumpy as legacy partnerships wind down. Expense discipline, particularly in R&D, will be critical to preserving the company's runway, which management has framed as extending into the second half of 2028. Overall, the story is increasingly defined by clinical execution rather than quarterly revenue, and investors will be watching for concrete progress toward a registrational trial. I'm watching this closely as the next data updates could shift sentiment meaningfully.
Exploring AI Tools for Biotech Research
In my own analysis of names like CytomX, I often turn to Tickeron’s AI Screener to quickly filter biotech peers by cash position, pipeline stage, and partnership activity. It helps surface comparable setups without spending hours on manual screens, and the AI-driven signals add a useful layer when evaluating clinical-stage companies. The tool’s customizable filters for fundamentals and trends make it straightforward to compare runway estimates or collaboration news across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTMX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CTMX turned positive on October 20, 2026. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Indicator exited the oversold zone, 31 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 64 cases where CTMX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +6.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in 182 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In 72 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CTMX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.544) is normal, around the industry mean (2.904). P/E Ratio (-3.754) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (27.624) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
Industry Biotechnology
Advertisement